Table 3 Anti-osteoporosis drug treatment in patients with fragility fracture during hospitalization

Cases, n

20,983

10,282

 N/A

3,839

3,495

 N/A

5,977

2,644

 N/A

5,623

1,963

 N/A

5,544

2,180

 N/A

Any anti-OP drug, n (%)

11,094 (52.87)

4,200 (40.85)

< 0.0001

1,732 (45.12)

1,099 (31.44)

< 0.0001

3,354 (56.12)

1,091 (41.26)

< 0.0001

3,222 (57.30)

940 (47.89)

< 0.0001

2,786 (50.25)

1,071 (49.13)

0.3738

Ca and/or ordinary VD, n (%)

3,259 (15.53)

1,503 (14.62)

0.0346

609 (15.86)

506 (14.48)

0.0988

935 (15.64)

381 (14.41)

0.1420

903 (16.06)

281 (14.31)

0.0668

797 (14.38)

305 (14.00)

0.6632

Active VD, n (%)

5,360 (25.54)

1,600 (15.56)

< 0.0001

779 (20.29)

327 (9.36)

< 0.0001

1,761 (29.46)

419 (15.85)

< 0.0001

1,636 (29.09)

397 (20.22)

< 0.0001

1,184 (21.36)

457 (20.96)

0.7038

Calcitonin, n (%)

6,276 (29.91)

2,241 (21.80)

< 0.0001

873 (22.74)

432 (12.36)

< 0.0001

1,866 (31.22)

581 (21.97)

< 0.0001

1,856 (33.01)

548 (27.92)

0.0007

1,681 (30.32)

641 (29.40)

0.4287

Bisphosphonates, n (%)

1,831 (8.73)

474 (4.61)

< 0.0001

273 (7.11)

69 (1.97)

< 0.0001

657 (10.99)

145 (5.48)

< 0.0001

521 (9.27)

135 (6.88)

0.0012

380 (6.85)

119 (5.46)

0.0247

Denosumab, n (%)

152 (0.72)

37 (0.36)

< 0.0001

16 (0.42)

11 (0.31)

0.4711

58 (0.97)

10 (0.38)

0.0042

48 (0.85)

8 (0.41)

0.0468

30 (0.54)

8 (0.37)

0.3248

Chinese medicine, n (%)

116 (1.13)

240 (1.14)

0.9028

78 (2.03)

74 (2.12)

0.7973

65 (1.09)

23 (0.87)

0.3540

47 (0.84)

11 (0.56)

0.2277

50 (0.90)

8 (0.37)

0.0142